Sponsored Videos

Our panel concludes by looking ahead to the next-generation tools and techniques shaping bioconjugate characterization.

The FDA’s 2026 draft guidance shifts more responsibility onto analytical characterization for product safety.

As bioconjugate drug manufacturing moves to scale, certain critical quality attributes (CQAs) are hardest to control.

Biophysical techniques can be used to catch bioconjugate aggregation and stability issues to prevent delays in drug development.

Two analytical experts explain how they use orthogonal methods to characterize bioconjugates without creating workflow bottlenecks.

Understand why a best-in-class antibody drug conjugate (ADC) depends on balancing antibody, linker, conjugation chemistry, and payload together.

Specific critical quality attributes (CQAs) matter most when designing an antibody drug conjugate (ADC) program for long-term success.

New conjugation chemistries and peptide-based linkers improve linker stability in antibody-drug conjugates (ADCs).

Experts trace how the bioconjugate field has transformed since 2016 and where it is headed next.

Meet the moderator for this Peer Exchange on Next-Gen Bioconjugation: Designing-in Analytical Precision and Efficiency.

Detra Glinatsis explains how a family-owned CDMO with 50 years of biologics experience is positioning clients for success in an era of tariffs and regulatory complexity.

Rich Kennedy, Simtra BioPharma Solutions, explains what sets a sterile injectable CDMO apart in a competitive manufacturing landscape.

Success in emerging biopharma depends not only on speed, but also on making confident, data-informed decisions early in development while managing increasing molecular complexity.

CDMOs are changing tactics in order to meet faster timelines, manage multiple manufacturing platforms, and navigate the industry's shift toward complex biologics.

Emily Schirmer, Catalent, explains how to accelerate the path to first-in-human trials as biologics pipelines grow more complex and timelines tighten.

Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner.

Campbell Bunce, CSO, Abzena, explains their integrated drug development model that combines front-end R&D with process development and manufacturing under one roof.

Successful tech transfer begins with early alignment, clear scope definition, and proactive risk management to ensure smooth progression from development to GMP manufacturing. By combining global expertise with local execution, Rentschler Biopharma delivers consistent quality, operational flexibility, and reduced risk for clients advancing complex therapies.

Explore how the sterile injectable manufacturing market is evolving to meet the dual demands of large-scale biologics and small-batch targeted therapies. In this video, Franco Negron of Simtra BioPharma Solutions shares insights on the trends, investments, and collaborations shaping the future of agile, resilient CDMO operations.

Conor Barry, PhD, Vice President and Global Head of R&D for Bioconjugates and Large Molecules at Piramal Pharma Solutions, discusses the evolving antibody-drug conjugate (ADC) landscape and how the company’s strategic investments and ADCelerate program are simplifying complex supply chains for global partners.

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

Discover how data governance and AI are transforming biologics manufacturing, from ensuring patient safety to improving process efficiency. Sundar Ramanan, PhD, MBA, Chief Quality Officer at Enzene, shares insights on leveraging data for quality, compliance, and collaboration between CDMOs and biotech innovators.

Scientific experts Katarzyna Darmochwal, PhD, and Carmen Sweeney, PhD, discuss the latest regulatory expectations for the analytical testing of biologics products. They explain why regulatory success depends not only on compliance, but also on the precision, reliability, and depth of scientific understanding behind every test method.